Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (abre nova janela)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Fonte‎: Ann Intern Med 2008;148(12):939-55.

Indexado‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (abre nova janela)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (abre nova janela)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Fonte‎: Am J Hematol 2000;64(1):26-31.

Indexado‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (abre nova janela)

Hydroxyurea for the treatment of sickle cell anemia. (abre nova janela)

Platt OS.

Fonte‎: N Engl J Med 2008;358(13):1362-9.

Indexado‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (abre nova janela)

Clinical effectiveness of decitabine in severe sickle cell disease. (abre nova janela)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Fonte‎: Br J Haematol 2008;141(1):126-9.

Indexado‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (abre nova janela)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (abre nova janela)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Fonte‎: Blood 2010;115(12):2354-63.

Indexado‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (abre nova janela)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (abre nova janela)

Hirst C, Owusu-Ofori S.

Fonte‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indexado‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (abre nova janela)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (abre nova janela)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Fonte‎: Lancet Haematol 2021;8(5):e323-33.

Indexado‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (abre nova janela)

Sickle cell disease. (abre nova janela)

Meremikwu MM, Okomo U.

Fonte‎: BMJ Clin Evid 2011;02:2402.

Indexado‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (abre nova janela)

A phase 3 trial of l-glutamine in sickle cell disease. (abre nova janela)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Fonte‎: N Engl J Med 2018;379(3):226-35.

Indexado‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (abre nova janela)

Malaria chemoprophylaxis in sickle cell disease. (abre nova janela)

Oniyangi O, Omari AA.

Fonte‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indexado‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (abre nova janela)